dasatinib

{
  "id": "MLC-T-ONC-002288",
  "term": "dasatinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs to treat adults and children aged 1 year and older with certain types of chronic myeloid leukemia or acute lymphoblastic leukemia that are Philadelphia chromosome positive. It is also being studied in the treatment of other types of cancer. Dasatinib blocks BCR::ABL1 and other proteins, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called BMS-354825 and Sprycel.",
    "An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes."
  ],
  "synonyms": [
    "BMS-354825",
    "Sprycel",
    "dasatinib hydrate",
    "dasatinib monohydrate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dasatinib/"
}